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THE COST-EFFECTIVENESS OF ELTROMBOPAG FOR THE TREATMENT 
OF CHRONIC ADULT IMMUNE THROMBOCYTOPENIC PURPURA (ITP) 
IN IRELAND
Hanley RM1, Redmond S1, Thompson G2
1GlaxoSmithKline, Dublin, Ireland; 2GlaxoSmithKline, Uxbridge, UK
OBJECTIVES: Immune thrombocytopenia (ITP) is a rare autoimmune disorder char-
acterised by low platelet counts resulting in symptoms that are usually minor, e.g. 
petechiae. However, patients with very low platelet counts face the risk of serious, 
but rare, bleeds, e.g. intracranial hemorrhage. The study objective was to estimate the 
cost-effectiveness of treating two groups of chronic adult ITP patients (refractory to 
splenectomy and where splenectomy is contraindicted) with oral eltrombopag versus 
romiplostim or rituximab from an Irish health care payer perspective. METHODS: A 
Markov model with a four week model cycle, two year time horizon and seven health 
states was used. In one arm, patients were treated with eltrombopag and in the other 
romiplostim or rituximab. Patients began in either the ‘controlled platelet’ or ‘uncon-
trolled platelet’ health states. Response rates from clinical trials (eltrombopag and 
romiplostim) and a published literature review (rituximab) determined whether 
patients were controlled or not. Controlled patients experienced a higher level of utility 
and lower risk of transitioning to bleed health states. Utilities (using the SF-36v2) for 
controlled/uncontrolled platelet levels were from the eltrombopag pivotal trial, RAISE. 
Utility for bleeds and costs were taken from the literature. Costs and beneﬁ ts were 
discounted by 4%. RESULTS: The model estimated that eltrombopag dominates 
romiplostim, i.e. cost savings of c13,000 and c18,000 with an incremental QALY of 
0.1 and 0.03 for patients who are refractory to splenectomy and where splenectomy 
is contraindicated respectively. This result was driven by the fact that eltrombopag is 
less expensive, does not incur wastage or administration costs and has slightly better 
durable response rates compared to romiplostim. Eltrombopag is not cost-effective 
compared to rituximab for both groups of patients because rituximab is signiﬁ cantly 
less costly than eltrombopag with comparable response rates. CONCLUSIONS: The 
economic model showed that eltrombopag dominates romiplostim but is not cost-
effective versus rituximab.
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OBJECTIVES: Uncertainty regarding the effectiveness of tyrosine kinase inhibitors 
(TKIs) for treatment of chronic myeloid leukemia (CML) has resulted in difﬁ culty for 
some appraisal committees to recommend second-line TKIs. Implementation of phar-
macogenomic-based diagnostics may facilitate individualized treatment with TKIs and 
improve overall treatment effectiveness. The objective of this economic evaluation was 
to estimate the potential cost-effectiveness of a companion diagnostic that predicts 
treatment response in CML patients eligible for dasatinib and nilotinib. METHODS: 
A decision analytic model was created to assess the cost-effectiveness of individualized 
treatment with dasatinib and nilotinib using a companion diagnostic test relative to 
current care (i.e., treat all patients with dasatinib until progression or no response, 
then treat with nilotinib). Transition probabilities and utility values were taken from 
published RCTs. The cost analysis included costs of treatment, response monitoring 
and the companion diagnostic. Scenario analyses were conducted to assess the impact 
of unavailable or highly uncertain values. RESULTS: Total costs and effects for the 
base-case analysis were c99,011 and 1.84 progression-free LYs (PF-LYs) and 1.63 
QALYs with the companion diagnostic strategy after a 2-year time horizon. In the 
current care situation, total costs and effects were c100,904 and 1.74 PF-LYs and 
1.61 QALYs. The companion diagnostic was the dominant strategy with a savings of 
approximately c4,000/PF-LY or c2,000/QALY. Scenario analyses revealed that the 
cost-effectiveness of the companion diagnostic is sensitive to time to response, time to 
progression and comparative effectiveness between dasatinib and nilotinib. CONCLU-
SIONS: Treatment of CML patients eligible for second-line TKIs using a companion 
diagnostic may be cost-effective. More precise estimates for uncertain or unavailable 
parameters should be incorporated when available. This case demonstrates the use of 
economic evaluation methods at early stages of technology development for internal 
decision-making and communicating the potential value of pharmacogenomic-based 
diagnostics to stakeholders.
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COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) 
COMPARED TO OXYCODONE AND MORPHINE IN PATIENTS WITH 
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OBJECTIVES: To assess the cost-effectiveness of tapentadol compared to oxycodone 
and morphine as 1st line strong opioid therapy in chronic non-cancer pain (CNCP) 
patients in Sweden. METHODS: A Markov transition state model over one year with 
cycle times of one month was built. Four health states were deﬁ ned: ‘occurrence of 
adverse events (AEs) with need for medical treatment’, ‘withdrawal due to AEs’, 
‘response to therapy’ and ‘death’. If patients did not adequately respond to tapentadol 
or comparators or withdrew, switching to alternative 2nd line opioid (oxycodone, 
morphine or transdermal fentanyl) was considered. After initiating 3rd line therapy, 
patients could stay on this therapy or die according to morbidity rate. Data regarding 
efﬁ cacy, tolerability and utility values (EQ-5D) were derived from clinical trials and 
published literature. Switch rates to subsequent opioid therapies and resource con-
sumption were estimated by clinical experts. Costs were calculated from the societal 
perspective. Direct costs were calculated based on ofﬁ cial Swedish prices/tariffs, indi-
rect costs were calculated based on ﬁ gures obtained from the literature and current 
wage rates. Costs and beneﬁ ts were not discounted in base-case calculation. Impact 
of selected parameters on the results was evaluated in one-way sensitivity analyses 
(OWSA). RESULTS: Mean annual total costs per patient amount to 242,583 SEK 
(Swedish krona) for tapentadol vs. 247,813 SEK for oxycodone and 246,093 SEK for 
morphine. Tapentadol generates 0.4712 QALYs compared to 0.4518 QALYs for 
oxycodone and 0.4535 QALYs for morphine. More QALYs generated in the model 
reﬂ ect tapentadol’s better tolerability proﬁ le than comparators. Cost parameter com-
prising physician visits, co-medications and non-drug therapy costs revealed highest 
impact in OWSA. CONCLUSIONS: Tapentadol, once approved, will generate more 
QALYs at lower costs than oxycodone and morphine. Tapentadol appears to be the 
favourable treatment option in the 1st line therapy of CNCP patients in Sweden from 
a societal perspective.
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OBJECTIVES: To evaluate the cost-effectiveness of duloxetine for the management 
of ﬁ bromyalgia assessed from the perspective of a health care payer in the United 
States. METHODS: A Markov model was used to evaluate the economic and clinical 
advantages in controlling ﬁ bromyalgia pain symptoms, considering duloxetine as an 
additional treatment option. The standard treatment sequence was deﬁ ned based on 
clinical guidelines including tricyclic antidepressants (TCAs), second-generation anti-
depressants (based on SNRIs), anticonvulsants, and opioid therapies. The model 
included 2 levels of pain response (a ≥30% and ≥50% change from baseline, using a 
standard 11-point severity scale). Clinical efﬁ cacy and discontinuation data were taken 
from a systematic literature review and mixed treatment comparison, including both 
placebo and active controlled trials. Utility data were linked to pain severity using 
trial-based EQ5D data. Discounting was applied at 3.0% per year. RESULTS: The 
introduction of duloxetine resulted in additional symptom-controlled months (SCMs), 
deﬁ ned as the amount of time at a ≥30% response level, and quality-adjusted life-years 
(QALYs), over a 2-year time horizon. First-line treatment resulted in an additional 
665 SCMs and 12.3 QALYs, with a cost of $582,911 ($877 per SCM and $47,560 
per QALY). Second-line treatment resulted in an additional 460 SCMs and 8.7 
QALYs, with a cost of $143,752 ($312 per SMC and $16,565 per QALY). a cost-
effectiveness frontier analysis suggested that second-line duloxetine is likely to be the 
most cost-effective option, however, in sensitivity analyses, the cost-effectiveness of 
ﬁ rst-line duloxetine improved when assumptions around continued treatment switch-
ing for long-term drop-outs were relaxed. CONCLUSIONS: There is currently a 
signiﬁ cant unmet need for patients with poorly controlled ﬁ bromyalgia where pain is 
a predominant symptom. These analyses show that the introduction of duloxetine into 
the standard treatment sequence for ﬁ bromyalgia can provide additional patient 
beneﬁ ts, which are cost-effective when compared to commonly adopted thresholds.
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OBJECTIVES: The objective of this analysis was to understand the economic conse-
quences of different products in primary prophylaxis in severe hemophilia A patients. 
Miners’ (2002, 2009) hemophilia economic Markov model was revised to compare 
two different factor VIII products—a full-length recombinant FVIII (Advate) and a B 
domain-deleted recombinant FVIII (BDDrFVIII) (Refacto AF). Based on documented 
differences in half life in a pharmacokinetic cross-over license study [1] with results 
submitted to EMA[2], this research evaluated the amount of clotting factor required 
to maintain the patient factor VIII trough levels above 1%. If a product has a shorter 
half-life, more clotting factor is required to prevent factor VIII levels falling below the 
minimum trough level. METHODS: The same basic model structure of Miners’ 
hemophilia economic Markov model was used to analyze the effects of differences in 
half-life in an Italian economic country setting, full-length recombinant FVIII (Advate) 
half-life 13.3 hours at a list price of c0.75 per IU versus BDDrFVIII (Refacto AF) 
half-life 11.2 hours at a list price of c0.69 per IU. The model considers the amount 
of factor required to prevent trough clotting factor levels from falling below 1%. 
RESULTS: The analysis estimated that the mean expected, discounted lifetime (70 
years) cost of primary prophylaxis in a severe hemophilia A patient was c0.88 million 
less using full length recombinant FVIII (Advate) when compared to a BDDrFVIII 
(Refacto AF), assuming a 2.1 hour shorter half-life; i.e. equal to over c12,500 in cost 
savings per patient per year. CONCLUSIONS: This analysis shows that prophylaxis 
therapy using full-length recombinant FVIII (Advate) may be cost saving compared to 
